Clinical trials and other observational studies have reported similar 3,4,6 or lower overall rates of hypoglycaemia 5,8 or a lower rate of nocturnal events 3,4 in GLP-1 receptor agonist versus insulin treatment. This evidence concerns the gene INS and Hypoglycemia.